关于第I类HDAC调节器的概述:抑制剂和降解剂
Ziqian Huang1, Limei Zeng2, Binbin Cheng3
1Department of Pharmacy, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China.
European journal of medicinal chemistry
|August 2, 2024
概括
针对I类基因组脱甲基酶 (HDACs) 的新策略对于癌症治疗至关重要. 本综述探讨了先进的抑制剂,包括双重作用和向蛋白质降解剂,以克服耐药性和毒性挑战.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 一类的基因组脱甲基酶 (HDACs) 在癌症等疾病中起着关键作用.
- 传统的HDAC抑制剂面临着挑战,包括耐药性,毒性和有限的疗效.
- 需要新的治疗策略,以有效地针对I类HDACs.
研究的目的:
- 为I类HDAC酶和抑制剂提供全面的概述.
- 审查用于癌症治疗的I类HDAC调节器的最新进展.
- 讨论第I类HDAC向药物发现的挑战和未来前景.
主要方法:
- 关于I类HDAC酶和抑制剂的文献综述.
- 分析最近在双作用抑制剂,向蛋白质降解 (TPD) 技术 (PROTACs,分子,HyT降解剂) 和共价抑制剂方面的进展.
- 审查合理设计原则,药理动力学,药理动力学和临床进展.
主要成果:
- 第I类HDAC是癌症药物开发中的关键目标.
- 像双作用抑制剂和TPDs这样的新策略在克服传统抑制剂的局限性方面表现出有希望.
- 异形选择性抑制剂,双抑制剂,TPD和共价抑制剂代表了显著的进步.
结论:
- 在I类HDAC调节器的进步为癌症治疗提供了新的途径.
- 有针对性的蛋白质降解和双重作用抑制剂是有希望的策略.
- 需要进一步的研究来应对挑战,并优化这些新型药物的临床应用.
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
727
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
727
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
952
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
952
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
812
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
812
Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555


